MediWound
Sector: Healthcare & Life Sciences
About MediWound
Enzymatic therapeutics for non-surgical tissue repair. Its solutions selectively remove non-viable hazardous tissue while preserving healthy tissue, offering a safer and more effective alternative to traditional methods. With robust in-house research, development, and manufacturing capabilities, the company produces and commercializes cutting-edge biologics for wound and burn care that exceed existing standards of care, improve patient outcomes, and reduce healthcare costs by eliminating the need for surgical interventions. (Nasdaq: MDWD)
Products
NexoBrid®; EscharEx®; Proteolytic Enzyme Platform
MediWound’s flagship product, NexoBrid®, is an FDA, EMA and PMDA approved orphan designated biologic, currently in use worldwide for treating severe burns. Building on its proprietary enzymatic technology, MediWound is advancing EscharEx®, a promising Phase III pipeline drug for the treatment of chronic wounds, including diabetic foot ulcers and venous leg ulcers.
Latest Company Updates
- MediWound Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
- NexoBrid-DETECT Study
- The Correlation Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers: A Post Hoc Analysis of the ChronEx Multicenter Randomized Controlled Trial
- EscharEx- Post Hoc Analysis